← Back to Search

Oxytocic Agent

Carbetocin for Uterine Atony

Phase 4
Waitlist Available
Led By Christian Loubert, MD, FRCPC
Research Sponsored by Maisonneuve-Rosemont Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 20 minutes
Awards & highlights

Study Summary

The purpose of this trial is to determine the effective dose of carbetocin which would prevent the occurrence of postpartum uterine atony in 90% of women undergoing an elective cesarean delivery.

Eligible Conditions
  • Uterine Atony
  • Postpartum Hemorrhage

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~20 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 20 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose of carbetocin which will prevent uterine atony in 90% of subjects
Secondary outcome measures
Additional uterine massage
Additional uterotonic medication administered
Anti nausea therapy
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: CarbetocinExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carbetocin
FDA approved

Find a Location

Who is running the clinical trial?

Université de MontréalOTHER
214 Previous Clinical Trials
102,731 Total Patients Enrolled
Maisonneuve-Rosemont HospitalLead Sponsor
99 Previous Clinical Trials
36,283 Total Patients Enrolled
Christian Loubert, MD, FRCPCPrincipal InvestigatorMaisonneuve-Rosemont Hospital
2 Previous Clinical Trials
50 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
ED90 Determination of Carbetocin for the Prevention of Uterine Atony in Women Undergoing an Elective Cesarean Delivery
Christian Loubert 2012. "ED90 Determination of Carbetocin for the Prevention of Uterine Atony in Women Undergoing an Elective Cesarean Delivery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01579201.
All > Liver Fibrosis
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top